AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Clodronate reduces risk of bone metastases in breast ca patients. (Bisphosphonate not on U.S. Market).
SAN ANTONIO -- Treatment with clodronate cut the incidence of bone metastases in women with breast cancer in a controlled study with more than 71,000 patients.
Women treated with clodronate, a bisphosphonate that's not yet available in this country, also had their rate of all-cause mortality cut by 23% during a median follow-up period of 5.5 years, Dr. Eugene V. McCloskey reported in a poster at the annual meeting of the American Society for Bone and Mineral Research.
The difference in mortality between the clodronate-treated and control groups fell just short of being statistically significant.
Clodronate is not approved for use in the United States, but is in the same class of drugs as approved agents such as alendronate and risedronate. The Finnish company that makes clodronate, Leiras, is considering seeking Food and Drug Administration approval for the drug, said Dr. McCloskey, a senior clinical research fellow in the metabolic unit of the University of Sheffield (England). Leiras funded the study that he reported.
The study included women with ...